Business Wire

LUNAPHORE-TECHNOLOGIES

23.5.2019 12:32:09 CEST | Business Wire | Press release

Share
Rapid Multiplexing with Opal® Research Kits Now Available on LabSat™ Platform

Lunaphore Technologies S.A., a Swiss medtech firm developing innovative next-generation equipment for cancer research and tissue diagnostics, announces a new rapid multiplexing application for its LabSat™ Research instrument.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190523005082/en/

Following the signature of a co-marketing agreement between Lunaphore Technologies S.A. and Akoya Biosciences, Inc.; Lunaphore will start providing multiplexing protocols using Akoya’s Opal® immunoassay kits for its staining platform LabSat™ Research, Lunaphore’s first solution to reach the market.

LabSat™ is shown to perform rapid tests on tissue samples under 2.5 hours for a 3-plex plus counterstaining with the Opal® 4-Color Manual IHC Kit; and under 4.5 hours for a 6-plex plus counterstaining with the Opal® 7-Color Manual IHC Kit1 . These timeframes present a 3 to 4-fold time improvement compared to the current turnaround times for Opal® 7-Color kit using manual protocols or other automation standards. During the study conducted by both companies, comparable intensity to other staining methods was observed, while reproducibility presented less than 20% of variability1 . Moreover, uniformity throughout the tissue section was tested with excellent results, obtaining a signal gradient under 10% over 1 cm of tissue1 . This opens opportunities for users to analyze images and quantify signals using Akoya’s imaging and software tools.

These short turnaround times are achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation, which allows researchers to perform rapid cycles of optimization in order to reach and repeat the desired multiplexed stainings, without the need to invest in traditional workflow automation instruments.

Lunaphore’s co-founder and CTO, Diego G. Dupouy, said: ”The great stainings obtained with our platform are the result of team effort by Lunaphore and Akoya, as we push both of our technologies to the next level. Our goal is to combine short turnaround times with high-quality stainings in order to enable researchers to develop their own immunophenotyping panels in unprecedented times.”

With the arrival of ultra-rapid automated multiplexing in LabSat™, Lunaphore brings together state-of-the-art multiplexing techniques, the high reproducibility of automation systems and an unmatched speed performance, now at the reach of medium and small laboratories.

About Lunaphore

Lunaphore Technologies S.A. is a Swiss company developing next generation tissue autostainers. The award-winning technology based on microfluidics is called FFeX (Fast Fluidic Exchange). It aims to perform assays much faster than standard techniques and has demonstrated good results in tests with cancer patient samples. Lunaphore was founded in 2014 with the vision of bringing –omics like approaches to tissue diagnostics and has been recognized as one of the most innovative companies nationally and internationally.

About LabSat™ Research

LabSat™ Research is a single-slide, ultra-rapid reagent delivery system performing IHC/IF tests on tissue samples for Research Use Only. The breakthrough speed performance of the device is achieved thanks to a novel microfluidic tissue processor lying at the core of Lunaphore’s innovation. This patented technology enables high precision tissue staining, with a drastic reduction of reagent incubation times.

About IHC/IF and multiplexing

Immunohistochemistry (IHC) staining is a technique that involves the use of antibodies to detect the presence of specific cancer biomarkers on a tissue sample. During an IHC test, the tissue is stained with labelled antibodies, producing a coloring on the tissue that is observable with a bright-field microscope. This coloring or staining will signal the presence and localization of specific cancer biomarkers within the tissue. Immunofluorescence (IF) is a similar technique which instead produces fluorescent stainings observable with a fluorescence microscope. IHC and IF are among the most common tests in immuno-oncology research to support scientists in the identification of specific cancer types.

In order to analyze the tumor microenvironment, understanding the spatial organization and co-expression of multiple biomarkers in a tissue section is of key importance. With this purpose, it is possible to stain and visualize several targets simultaneously with a technique known as multiplexed IHC or IF. With Akoya’s Opal® fluorescent kits -4-color and 7-color- 3 and 6 biomarkers, respectively, can be stained at once in order to maximize the obtention of information from each tissue section.

Disclaimer: LabSat™ Research is approved for Research Use Only and not available for diagnostic procedures. Only marketed in Europe.

1 Data on file.

Contact:

Irene Tamayo Lunaphore Corporate Communications Email: communications@lunaphore.com Phone: +41 21 353 58 22

Andrea Büchler Lunaphore Finance and Business Development Email: andrea.buechler@lunaphore.com Phone +41 79 598 40 73

Link:

ClickThru

Social Media:

https://www.facebook.com/lunaphore

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference9.10.2026 19:15:00 CEST | Press release

- Data on ALYFTREK in children ages 2 to 5 years demonstrate recovery of pancreatic function in some children –- Additional abstracts on clinical and real-world evidence on CFTR modulators also presented - Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced new interim data from the ALYFTREK® (vanzacaftor/tezacaftor/deutivacaftor) 2 to 5 years old open-label extension study, highlighting recovery of exocrine pancreatic function in some children in that age group, allowing those children to discontinue pancreatic enzyme replacement therapy (PERT). Pancreatic exocrine insufficiency in children with cystic fibrosis (CF) was previously believed to be irreversible. These data were presented at the North American Cystic Fibrosis Conference (NACFC). “The data presented at NACFC underscore the safety and efficacy of our CF medicines in the real world and in clinical trials in younger age groups. The data from the Phase 3 open-label study in 2 to 5 year olds evaluating exocrine p

Andersen Consulting udvider med TalentSmartEQ for at fremme lederskab og virksomhedstransformation9.10.2026 18:48:00 CEST | Pressemeddelelse

Andersen Consulting styrker sine kompetencer inden for humankapital gennem en samarbejdsaftale med TalentSmartEQ, en San Diego-baseret virksomhed, der har fokus på at skabe praktiske, engagerende og handlingsorienterede læringsoplevelser med udgangspunkt i emotionel intelligens (EQ) og lederudvikling. I mere end to årtier har TalentSmartEQ arbejdet sammen med organisationer verden over med henblik på at udvikle ledelseskompetencer ved hjælp af emotionel intelligens og dermed styrke medarbejderengagement, teamwork og de samlede resultater. Virksomheden kombinerer forskningsbaserede metoder med praktiske læringsforløb, vurderinger, coaching og skræddersyede programmer, der skal omsætte opbygningen af emotionel intelligens til vedvarende ændringer i adfærden på arbejdspladsen. Som førende aktør i branchen samarbejder TalentSmartEQ med organisationer lige fra Fortune 500-virksomheder til offentlige myndigheder og privatejede virksomheder. "Organisationer stiller stadig større krav til dere

Verdant Rock Receives A (low) Financial Strength Rating from Morningstar DBRS, Adding a Second International Investment-Grade Assessment9.10.2026 16:00:00 CEST | Press release

Verdant Rock now holds Financial Strength Ratings from both Fitch Ratings and Morningstar DBRS, providing counterparties with dual-agency confirmation and reinforcing the security architecture behind each financial guarantee Verdant Rock Limited, a Bermuda Monetary Authority-regulated Class 3B insurance company, has received an A (low) Financial Strength Rating from Morningstar DBRS. The rating reflects Verdant Rock’s financial strength and its capacity to meet policyholder obligations as an investment-grade financial guarantor for Emerging Markets credit. Morningstar DBRS is a global credit rating agency with coverage across North America, Europe, Asia, and Latin America. Its assessment of Verdant Rock reflects the company’s strong projected earnings ability, robust risk profile, sound liquidity, and good capitalization. Morningstar DBRS also assigned an A (low) Issuer Rating to Verdant Rock. The rating follows Verdant Rock’s BBB+ Long-Term Insurer Financial Strength Rating with a Sta

Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions9.10.2026 15:17:00 CEST | Press release

We think Gartner recognizes Tecnotree's open, governed approach to agentic AI as operators make AI the engine of their revenue operations Tecnotree, a global digital platform and services leader for AI, 5G, and cloud-native technologies, today announced that Gartner has positioned it as a Visionary in the first-ever Magic Quadrant for AI-Enabled CSP Marketing and Sales Solutions. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261009905430/en/ Tecnotree Named a Visionary in the Inaugural 2026 Gartner® Magic Quadrant™ for CSP AI-Enabled Marketing and Sales Solutions A new category for a new operating model. CSPs are fighting saturated markets, rising acquisition costs, and accelerating churn. They are responding with AI-driven automation across the full revenue cycle, from segmentation and campaigns to lead management, CPQ, and renewals, increasingly executed by autonomous agents. According to us, Gartner creation of this Magi

Positive New Data on Corcym’s Perceval Plus Sutureless Aortic Heart Valve Encompasses up to 7-Year Follow-up9.10.2026 15:15:00 CEST | Press release

Data Presented at Annual Meeting of European Association for Cardio-Thoracic Surgery (EACTS), Along with 6 Perceval Plus E-PostersEACTS Also Marks Commercial Launch of TriMemo and Memo 4D Curve, Innovative Repair Devices for Tricuspid and Mitral Valves Corcym, a global medical device company dedicated to cardiac surgery, today announced that positive mid-term data from a sub-analysis of its Perceval Plus sutureless aortic heart valve as part of its MANTRA clinical trial was featured in an oral presentation today at the annual meeting of the European Association for Cardio-Thoracic Surgery (EACTS). The study is the longest follow-up available for Perceval Plus and the FREE tissue treatment from an international multicenter study, and demonstrated excellent durability, safety and quality of life improvements. Perceval Plus is the only sutureless and collapsible aortic surgical heart valve. Its unique design performs in any surgical scenario and is optimal for endoscopy and robotics. The

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye